Cargando…

Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome

BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickey, Brittney L., Sirak, Bradley, Martin-Gomez, Laura, Reich, Richard R., Abrahamsen, Martha, Isaacs-Soriano, Kimberly, Chung, Christine H., Giuliano, Anna R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253433/
https://www.ncbi.nlm.nih.gov/pubmed/34214131
http://dx.doi.org/10.1371/journal.pone.0254161
_version_ 1783717511421755392
author Dickey, Brittney L.
Sirak, Bradley
Martin-Gomez, Laura
Reich, Richard R.
Abrahamsen, Martha
Isaacs-Soriano, Kimberly
Chung, Christine H.
Giuliano, Anna R.
author_facet Dickey, Brittney L.
Sirak, Bradley
Martin-Gomez, Laura
Reich, Richard R.
Abrahamsen, Martha
Isaacs-Soriano, Kimberly
Chung, Christine H.
Giuliano, Anna R.
author_sort Dickey, Brittney L.
collection PubMed
description BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment. METHODS: A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes. RESULTS: In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44–106.72; T3: OR: 9.86; 95% CI: 1.13–85.90) among all cases, but not among P16+ cases. CONCLUSIONS: Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response.
format Online
Article
Text
id pubmed-8253433
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82534332021-07-13 Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome Dickey, Brittney L. Sirak, Bradley Martin-Gomez, Laura Reich, Richard R. Abrahamsen, Martha Isaacs-Soriano, Kimberly Chung, Christine H. Giuliano, Anna R. PLoS One Research Article BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment. METHODS: A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes. RESULTS: In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44–106.72; T3: OR: 9.86; 95% CI: 1.13–85.90) among all cases, but not among P16+ cases. CONCLUSIONS: Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response. Public Library of Science 2021-07-02 /pmc/articles/PMC8253433/ /pubmed/34214131 http://dx.doi.org/10.1371/journal.pone.0254161 Text en © 2021 Dickey et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Dickey, Brittney L.
Sirak, Bradley
Martin-Gomez, Laura
Reich, Richard R.
Abrahamsen, Martha
Isaacs-Soriano, Kimberly
Chung, Christine H.
Giuliano, Anna R.
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title_full Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title_fullStr Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title_full_unstemmed Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title_short Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
title_sort oral secretory leukocyte protease inhibitor (slpi): associations with oropharyngeal cancer and treatment outcome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253433/
https://www.ncbi.nlm.nih.gov/pubmed/34214131
http://dx.doi.org/10.1371/journal.pone.0254161
work_keys_str_mv AT dickeybrittneyl oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT sirakbradley oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT martingomezlaura oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT reichrichardr oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT abrahamsenmartha oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT isaacssorianokimberly oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT chungchristineh oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
AT giulianoannar oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome